{"title":"Intense Prostate-specific Membrane Antigen Avid Hepatic Metastatic Lesions Shortly After Finishing 6 Cycle Pluvicto Treatment: Challenging and Reflects.","authors":"Xiaofei Wang, Thomas Hogan, Kody Heubach","doi":"10.1097/RLU.0000000000005789","DOIUrl":null,"url":null,"abstract":"<p><p>A 71-year-old man was diagnosed with prostate cancer in 2012. After treatment with hormone, chemo, and combinations subsequently, the baseline prostate-specific membrane antigen PET scan revealed 130+ nodal and osseous metastatic lesions. After 4 doses of pluvicto, a partial response was appreciated. However, new intense prostate-specific membrane antigen avid hepatic lesions occupied around 30% of the liver with poorly differentiated metastatic prostate cancer 55 days after the last dose of pluvicto and markedly elevated prostate-specific antigen. This case highlights the need for vigilant monitoring and alternative treatment strategies.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"523-524"},"PeriodicalIF":9.6000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005789","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
A 71-year-old man was diagnosed with prostate cancer in 2012. After treatment with hormone, chemo, and combinations subsequently, the baseline prostate-specific membrane antigen PET scan revealed 130+ nodal and osseous metastatic lesions. After 4 doses of pluvicto, a partial response was appreciated. However, new intense prostate-specific membrane antigen avid hepatic lesions occupied around 30% of the liver with poorly differentiated metastatic prostate cancer 55 days after the last dose of pluvicto and markedly elevated prostate-specific antigen. This case highlights the need for vigilant monitoring and alternative treatment strategies.
期刊介绍:
Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty.
Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.